Medsolve Dynamics

Price the AI, Not the Demo: Two Questions Before You Buy Theranostics Response-Monitoring Software

Medsolve Dynamics — Mon, 13 Jul 2026 18:00:00 GMT

Yoel Bakas, computer science and an MBA in artificial intelligence, twenty years configuring and pricing this class of technology from the vendor side, on the two questions radiation oncology and theranostics programs should ask before buying AI response-monitoring or workflow software: does it have a billing pathway (or is it an operating expense with no code to bill against), and who owns the output when the software touches a clinical decision. For hospital and freestanding radiation oncology administrators, CFOs, and theranostics program leads evaluating AI, software renewals, and capital vs operating spend. medsolvedynamics.com | team@medsolvedynamics.com

Running the Theranostics Plan at Drug Margin Zero

Medsolve Dynamics — Wed, 08 Jul 2026 18:00:00 GMT

The CY 2027 OPPS proposed rule puts the 340B drug spread underneath hospital theranostics programs on the table. Two drugs carry the category, Pluvicto and Lutathera, and for many programs the spread is what made the line lucrative. This episode covers the discipline: nobody tears up a program on a proposed rule, and nobody signs capital before checking whether the plan still works if the rule sticks. Three drug prices to test before the FY28 budget locks, and what a theranostics business plan has to stand on when the drug margin goes to zero. medsolvedynamics.com | team@medsolvedynamics.com

The Tell in a LINAC Service Contract: Same Rate on a New Machine and a Twenty-Year-Old One

Medsolve Dynamics — Fri, 26 Jun 2026 15:58:33 GMT

A radiation oncology service contract that quotes the same rate on a one-year-old LINAC and a twenty-year-old one was never priced on the cost to serve the machine. It was priced to anchor you. How to make a LINAC service price prove it is tied to cost. LINAC service contract, service pricing, capital negotiation, vendor negotiation, AMAC, purchasing framework.

medsolvedynamics.com

team@medsolvedynamics.com

Why a One-Hour LINAC downtime Becomes a Three-Hour Day in Radiation Oncology

Medsolve Dynamics — Fri, 26 Jun 2026 18:00:00 GMT

Parts lead time and field-engineer coverage, not the uptime percentage in your contract, decide how long a LINAC is actually down. A vendor-side look at how service coverage models are built around the vendor's cost, not your schedule, and what that costs your throughput and margin. LINAC downtime, service coverage, parts logistics, field engineer, uptime SLA, throughput, time toxicity.

medsolvedynamics.com

team@medsolvedynamics.com

What Every New Radiation Oncology Administrator Should Know Before Their First Vendor Meeting

Medsolve Dynamics — Fri, 19 Jun 2026 18:00:00 GMT

Your first capital negotiation is against someone who runs forty a year. This explains where the vendor puts the leverage and how a new administrator levels the field. New administrator, capital negotiation, vendor meeting, supervision coverage, radiation oncology.

Why a Discount Off List Is Not a Number You Can Trust in Radiation Oncology Capital

Medsolve Dynamics — Wed, 17 Jun 2026 18:00:00 GMT

A percentage off a list price the vendor set themselves tells you very little. This explains why the value package matters more than the discount in a LINAC capital negotiation, and what a program should structure for instead. Capital strategy, vendor quote, service contract, radiation oncology.

medsolvedynamics.com
team@medsolvedynamics.com

Why AI Efficiency Disappears Between the Demo and the Staffing Model.

Medsolve Dynamics — Thu, 11 Jun 2026 18:00:00 GMT

Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology.

medsolvedynamics.com | team@medsolvedynamics.com

#AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations

Why a Radioligand No-Show Costs Differently Than a Missed Fraction.

Medsolve Dynamics — Thu, 11 Jun 2026 13:58:07 GMT

Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply.

medsolvedynamics.com | team@medsolvedynamics.com

#Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations

Why AI Is Not a One-Time Purchase in Radiation Oncology

Medsolve Dynamics — Thu, 04 Jun 2026 16:00:00 GMT

AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo.

medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI

Why a Theranostics No-Show Hurts Differently Than an IMRT One

Medsolve Dynamics — Wed, 03 Jun 2026 18:00:00 GMT

In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out.

medsolvedynamics.com | team@medsolvedynamics.com

#Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations

A Guideline Says It Is Appropriate. The Next Question Is Whether Your Program Can Deliver It.

Medsolve Dynamics — Tue, 02 Jun 2026 16:00:00 GMT

A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule.

medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #Osteoarthritis #ServiceLineGrowth #BenignDisease

The Service Contract Renewal Conversation Most Rad Onc Programs Have Already Lost

Medsolve Dynamics — Thu, 28 May 2026 18:00:00 GMT

Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time against contracted SLA. Preventive maintenance hours delivered against contracted hours. Parts coverage against parts billed extra. First-call resolution rate. Pull the data quarterly, reconcile against contract spec, build the quarterly service review around the gap.

medsolvedynamics.com | team@medsolvedynamics.com

The Vendor Landscape Just Widened. Your Capital Conversation Changed Whether You Know It Or Not.

Medsolve Dynamics — Wed, 27 May 2026 18:00:00 GMT

At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing because of what showed up in Berlin. What changed is the leverage map on every conversation around them.

medsolvedynamics.com | team@medsolvedynamics.com

The Hospital Math Says Build. The Physician Math Says Do Not. That Gap Is The wRVU Trap.

Medsolve Dynamics — Wed, 27 May 2026 00:37:02 GMT

Most rad onc programs sitting on soft Q2 numbers are looking outside the building for offsetting revenue. The infrastructure for radioligand therapy is already inside the building, and a Jefferson-authored paper accepted by Practical Radiation Oncology in May 2026 puts the 340B-eligible hospital gross margin at roughly $101,000 per Pluvicto patient over a full course. The same paper names why programs stall. The rad onc on a dollars-per-wRVU comp model takes a 26-wRVU haircut against EBRT for picking up RPT. The credential map is already in the department. The comp model discussion is in the way. The operator move is to renegotiate the comp model with the 340B margin as the leverage before the service line gets approved.

medsolvedynamics.com | team@medsolvedynamics.com

Ask The Vendor What The Same Software Costs Without The AI. The Unbundled-Price Question

Medsolve Dynamics — Thu, 21 May 2026 16:00:00 GMT

From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price.

medsolvedynamics.com | team@medsolvedynamics.com

When I Was On The Vendor Side: The AI Demo That Skipped The Workflow Question

Medsolve Dynamics — Tue, 19 May 2026 16:00:00 GMT

A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision.

medsolvedynamics.com | team@medsolvedynamics.com

Why Your LINAC's Unbooked Hours Are The Cheapest Margin Audit You Will Run In 2026

Medsolve Dynamics — Mon, 18 May 2026 16:00:00 GMT

From 20 years on the vendor side of LINAC capital and service negotiations, the data point most radiation oncology programs do not see with the same precision the vendor sees it: their own unbooked machine hours. Every unbooked hour is a fixed cost paid for and not recovered. The 15-minute utilization audit is the cheapest margin discipline in the 2026 reimbursement environment.

medsolvedynamics.com | team@medsolvedynamics.com

What Does This Commit Us To In Year Five? The Question Every Oncology Capital Decision Needs

Medsolve Dynamics — Fri, 15 May 2026 18:00:00 GMT

Capital decisions hold up when the year-five reality is considered before the signature. They break when only year-one numbers are. From 20 years on the vendor side and now on the program side, the year-five question that protects margin through a multi-year operating commitment in radiation oncology.

medsolvedynamics.com | team@medsolvedynamics.com

The Proforma Altitude Problem In 2026 Oncology Capital Decisions

Medsolve Dynamics — Wed, 13 May 2026 18:00:00 GMT

From 20 years on the vendor side and now on the program side, the math that wins capital approval is not the math the program runs in year two. The reimbursement environment moved more than the headline rate change.

medsolvedynamics.com | team@medsolvedynamics.com

Adding Benign Disease Is A Referral Decision, Not An Equipment Decision

Medsolve Dynamics — Tue, 12 May 2026 18:00:00 GMT

Benign disease radiation uses LINAC capacity that is already paid for in most programs. The growth question is referral pathway, not capital. From 20 years of watching programs add and grow service lines.
medsolvedynamics.com | team@medsolvedynamics.com

Theranostics Capital Decisions Are Build-Or-Partner Decisions, Not Product Decisions

Medsolve Dynamics — Mon, 11 May 2026 16:00:00 GMT

From 20 years on the vendor side and now on the program side, the capital form decision that gets skipped on most theranostics service-line additions. Build or partner sets the next decade. With reference to Kenneth Brooks and Christine Stone’s published build case study at Wellstar Health System. medsolvedynamics.com | team@medsolvedynamics.com

Capital Is A 7-10 Year Commitment: The Math Most Proformas Skip

Medsolve Dynamics — Fri, 08 May 2026 18:00:00 GMT

Capital decisions in radiation oncology are not point-in-time decisions. The proforma that wins approval at signature is not the proforma that runs the program in year five. From 20 years on the vendor side and now on the program side, the math that protects margin through a full capital cycle.

medsolvedynamics.com | team@medsolvedynamics.com

Why Vendor Proformas Don’t Survive Year Two: A Capital Decision Reality Check

Medsolve Dynamics — Tue, 05 May 2026 16:00:00 GMT

The capital case in a vendor proforma is usually solid. The operating case is rarely modeled. From 20 years on the vendor side selling these programs, here is the operational reality that shows up in year two and never lives in the original proforma. Applies to LINAC purchases, theranostics expansions, and benign disease program builds.

medsolvedynamics.com | team@medsolvedynamics.com

After 20 Years Selling LINACs, This Is What I Saw From The Vendor Side

Medsolve Dynamics — Thu, 07 May 2026 16:00:00 GMT

A moment from the AMAC Spring Symposium 2026 talk on the day I told a room of oncology administrators that I have watched programs lose margin on contracts I helped sell them. Plus the 17-year ROI case study. medsolvedynamics.com | team@medsolvedynamics.com

Why The Old Capital Math Does Not Survive The 2026 Reimbursement Environment

Medsolve Dynamics — Wed, 06 May 2026 18:00:00 GMT

A short clip from the AMAC Spring Symposium 2026 talk on the discipline programs need to apply to every capital decision in the current environment. Forward-looking, not policy-blame.

medsolvedynamics.com | team@medsolvedynamics.com

Where Volume Responsibility Belongs in an Oncology Program | Jeff Siupik

Medsolve Dynamics — Mon, 04 May 2026 14:15:00 GMT

Jeff Siupik, 35 years in oncology operations, on where volume responsibility actually belongs in a healthy program. The C-suite looks at P&L. The clinical team looks at compassionate care. Where leaders most often misallocate the volume expectation, and where it should sit instead.

Full episode: https://youtu.be/9bPM8rjsv6Y

medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #OncologyLeadership #HealthcareExecutive #OncologyOperations

Running a Cancer Program in 2026: Capital, Operations, and the Job Behind the P&L

Medsolve Dynamics — Mon, 04 May 2026 13:30:00 GMT

Yoel Bakas sits down with Jeff Siupik, a healthcare executive with 35 years in oncology operations and 25 years in oncology leadership. Jeff has put in eight to ten linear accelerators across his career, led oncology programs through every reimbursement shift since the early 1990s, and currently oversees operations across a multi-program system.

The conversation walks through the actual job of an oncology administrator in 2026.

The balance between growth and expense control. Why P&L looks worse before it looks better when a program is in growth mode, and what most administrators are explaining to finance committees right now.

How to read your operation when the metrics look green. The stoplight framework Jeff uses for evaluating efficiency, and why a green department can still have staff running in the red line of mental capacity.

The disconnect between the C-suite and the clinical team. Where volume responsibility actually belongs in a healthy program, and where leaders most often misallocate it.

Capital decisions in radiation oncology. What separates the programs that get capital right from the ones that do not. Service contracts, software licensing, the ongoing-cost trap, and creative offsets like block leases.

AI in oncology operations. A pragmatic take on what AI is actually doing in cancer programs right now versus what is being pitched. Where AI creates time, where it slows things down, and how to think about the patient-side implications.

A worked example of how a leadership team handles competing capital requests across service lines, and why “every specialty feels their request is the highest priority” is the room every administrator is in.

Yoel and Jeff have known each other for over a decade across the vendor and operator sides of radiation oncology. This is operator-thinking from someone who has lived the job.

22 minutes. Worth the time for any administrator, medical director, or system executive running an oncology program in 2026.

Medsolve Dynamics: medsolvedynamics.com Reach the team: team@medsolvedynamics.com

#RadiationOncology #OncologyLeadership #CapitalStrategy #HealthcareExecutive #OncologyOperations

Staff Is The Soul Of Your Program: Capital Discipline For Oncology Hiring And AI Tools

Medsolve Dynamics — Thu, 30 Apr 2026 18:00:00 GMT

Hiring and retention decisions are landing on the same desks as AI tool decisions, often in the same week. After 20 years on the vendor side, here is the discipline most programs are missing: the same questions you would ask of any capital line, applied to the people on the team and the tools being sold to replace them. medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #OncologyLeadership #StaffPlanning #FinancialStrategy

The Service Contract Autopilot Problem: A 14-Year Veteran Explains

Medsolve Dynamics — Wed, 29 Apr 2026 18:00:00 GMT

From the Medsolve Dynamics conversation with Heather Turner, radiation oncology operator with 14 years from therapist to director. The contracts are not the problem. The autopilot is. medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #ServiceContracts #VendorNegotiation #OncologyLeadership

I Loved Selling Bundles: 20 Years On The Vendor Side Of LINAC Capital

Medsolve Dynamics — Tue, 28 Apr 2026 18:00:00 GMT

The economic case for a LINAC purchase rarely fails at signature. It fails in years two through eight, when the bundled add-ons start collecting service contracts and software renewals. After 20 years on the vendor side, here is what the inside of that conversation looks like, and why bundles are designed exactly this way. medsolvedynamics.com | team@medsolvedynamics.com

#RadiationOncology #LINAC #CapitalStrategy #VendorNegotiation #OncologyLeadership

Negotiating Inside a Structure the Vendor Built Before You Arrived

Medsolve Dynamics — Thu, 23 Apr 2026 15:30:00 GMT

Most oncology capital and service negotiations are decided before anyone sits down. Vendor teams map your budget range, rehearse responses to your objections, and identify pricing flexibility they never surface unless you ask the right way.

Yoel Bakas spent 20+ years on the vendor side of those conversations at Varian, GE HealthCare, ViewRay, and Mevion before founding Medsolve Dynamics. In this short, he lays out what actually happens in the prep call two days before your meeting, and why harder negotiating rarely changes the outcome.

Medsolve Dynamics is a vendor-neutral oncology consulting firm built for programs navigating margin pressure, capital scrutiny, and AI overload.

medsolvedynamics.com team@medsolvedynamics.com

#RadiationOncology #CapitalStrategy #VendorNegotiation #LINAC #OncologyLeadership

After 20 Years on the Vendor Side, What Medsolve Does for Cancer Programs

Medsolve Dynamics — Wed, 22 Apr 2026 15:15:00 GMT

After 20 years on the vendor side of oncology at GE HealthCare, ViewRay, and Varian, Yoel Bakas launched Medsolve Dynamics to work from your program side. In this episode, he walks through what Medsolve actually does: capital strategy on LINAC and theranostics purchases, service contract renegotiation before escalator clauses compound, financial case building for theranostics and benign disease service lines before capital is committed, and AI and software evaluation on clinical value and ROI rather than vendor claims. If you have a capital decision, a service contract renewal, a new service line, or an AI evaluation in front of you right now, this is who Medsolve was built for. LINAC capital strategy, oncology vendor negotiation, radiation oncology service contracts, theranostics service line, benign disease radiation therapy, AI in oncology, hospital operations. medsolvedynamics.com | team@medsolvedynamics.com

Why Most Oncology Service Contracts Quietly Cost Programs Money

Medsolve Dynamics — Tue, 21 Apr 2026 15:15:00 GMT

Most oncology service contracts renew automatically unless a specific window is used to renegotiate. Yoel Bakas, founder of Medsolve Dynamics, walks through the specific mechanics of a renewal clock that most program administrators miss until it has already closed — and what a single overlooked provision on page 7 cost one cancer program. Twenty years on the vendor side of oncology means knowing where the escalators, auto-renewals, and quiet cost increases are written into the fine print, and where the leverage lives before the next signature. LINAC service contracts, oncology service renewal, radiation oncology operations, capital strategy. medsolvedynamics.com | team@medsolvedynamics.com

AI Procurement Accountability in Healthcare: 3 Questions Before You Sign

Medsolve Dynamics — Tue, 14 Apr 2026 18:30:00 GMT

The conversation highlights the pitfalls of AI procurement, the consequences of procurement failure, misleading claims in AI sales, and key questions for procurement. It emphasizes the importance of considering adoption requirements and the impact on workflow when purchasing AI solutions.

Takeaways

Procurement failure
Adoption requirements

medsolvedynamics.com

team@medsolvedynamics.com

Can you afford it at 80% of the current reimbursement?

Medsolve Dynamics — Fri, 10 Apr 2026 16:15:00 GMT

The conversation explores the critical question of whether decisions hold up at 80% of the current reimbursement, emphasizing the importance of considering this in every capital decision and service renewal.

Takeaways

Financial decisions must consider sustainability at 80% reimbursement
Every purchase decision should be evaluated based on sustainability at 80% reimbursement

medsolvedynamics.com

team@medsolvedynamics.com

The allure of new technology without a clear problem to solve!

Medsolve Dynamics — Thu, 09 Apr 2026 15:00:00 GMT

A physicist's excitement about a new tool without a clear problem to solve.

Takeaways

Tool adoption without a clear problem
The allure of new technology

medsolvedynamics.com

team@medsolvedynamics.com

Preparation and Anticipation in Vendor Negotiations

Medsolve Dynamics — Wed, 08 Apr 2026 15:00:00 GMT

Preparation and Anticipation in Negotiations

Takeaways

Preparation is key
Anticipate objections

medsolvedynamics.com

team@medsolvedynamics.com

Key provisions that can have a significant financial impact.

Medsolve Dynamics — Tue, 07 Apr 2026 15:15:00 GMT

The conversation explores the impact of contracts on margins and highlights the importance of paying attention to contract details, especially key provisions that can have a significant financial impact.

Takeaways

Contract provisions can have significant financial impact
Importance of paying attention to contract details

medsolvedynamics.com
team@medsolvedynamics.com

Defining the problem before pricing is crucial.

Medsolve Dynamics — Wed, 01 Apr 2026 19:45:00 GMT

The conversation emphasizes the importance of answering key questions before requesting a quote from a vendor, highlighting the vendor's influence on unanswered questions and the significance of defining the problem before pricing. It also mentions an upcoming presentation at the AMAC® Spring Symposium.

Takeaways

Answer key questions before engaging with vendors
Defining the problem before pricing is crucial

medsolvedynamics.com

team@medsolvedynamics.com

Inside Oncology Operations: What Programs Are Dealing With Right Now | Heather Turner

Medsolve Dynamics — Tue, 31 Mar 2026 14:30:00 GMT

Heather Turner has 14 years of experience in radiation oncology. Radiation therapist, operations manager for a new cancer center build, director. In this conversation she and Yoel Bakas talk about the real challenges programs are navigating in 2026. Staffing shortages across therapists, dosimetrists, physicists, and physicians. Workflow breakdowns between radiation oncology, medical oncology, and imaging. The administrative burden of prior authorization. AI tools being purchased before the problem is defined. Service contracts that have not been reviewed since signature. And the pressure of buying equipment when reimbursement just changed the math.

medsolvedynamics.com

team@medsolvedynamics.com

#RadiationOncology #OncologyOperations #OncologyLeadership #HealthcareStrategy #VendorNegotiation #CapitalStrategy #Theranostics #HospitalOperations

Getting beyond price in vendor negotiations.

Medsolve Dynamics — Thu, 26 Mar 2026 17:30:00 GMT

In the context of radiation oncology capital conversations, the focus on price often overshadows other critical factors such as service coverage, software license terms, training, and delivery timelines. Vendors have already modeled the price negotiation and have a floor in mind, leading to a conversation that stays within their designed model.

Takeaways

Price conversation overshadows critical factors
Vendors have already modeled price negotiation

How to avoid financial losses and unexpected escalations from your service contract.

Medsolve Dynamics — Tue, 24 Mar 2026 17:30:00 GMT

Understanding the key provisions in a service contract is crucial to avoid financial losses and unexpected escalations. Four common provisions, including the Evergreen Clause, CPI escalator, bundled software license, and Uptime SLA Definition, can have significant financial implications if not carefully reviewed and understood.

Takeaways

Key provisions in service contracts can have significant financial implications.
Reading and understanding the entire contract before renewal conversations is crucial.

The asymmetry in sales conversations & the need for program leaders to have support.

Medsolve Dynamics — Tue, 24 Mar 2026 17:30:00 GMT

The conversation delves into the asymmetry in sales conversations, the structural information asymmetry, and the need for program leaders to have support when navigating major capital decisions or service contract renewals.

Takeaways

Sales conversations are characterized by asymmetry
Program leaders need support in major decisions

Programs that document performance gaps can negotiate from a position of strength.

Medsolve Dynamics — Tue, 17 Mar 2026 13:04:28 GMT

Customer experience drives 53% of purchase decisions, not clinical superiority. This is particularly relevant for radiation oncology programs. Programs that document performance gaps can negotiate from a position of strength.

Takeaways

Customer experience is a key factor in purchase decisions
Documented performance gaps empower negotiation

The importance of defining success and the problem before engaging in pricing discussions.

Medsolve Dynamics — Tue, 17 Mar 2026 13:03:25 GMT

The conversation delves into the misconceptions and limitations of requesting a quote from a vendor, highlighting the importance of defining success and the problem before engaging in pricing discussions.

Takeaways

Vendor Perspective
Importance of Defining Success

The margin structure of LINAC service contracts and its impact on negotiations.

Medsolve Dynamics — Tue, 17 Mar 2026 13:02:51 GMT

Understanding the margin structure of LINAC service contracts and its impact on negotiations.

Takeaways

Service contracts are highly profitable for vendors.
Knowing the margin structure can impact negotiation outcomes.

Leveraging contracts and KPI tracking is essential for program success.

Medsolve Dynamics — Tue, 17 Mar 2026 13:01:18 GMT

Oncology programs often have service contracts with major vendors, but lack active tracking of vendor performance. Key performance indicators (KPIs) such as uptime guarantees, response times, maintenance windows, and parts availability are critical levers for negotiation. Documented performance gaps lead to better outcomes than frustration-driven interactions. Leveraging contracts and KPI tracking is essential for program success.

Takeaways

Vendor performance tracking is crucial
Documented performance gaps lead to better outcomes

Reevaluate assumptions and review budget numbers in response to budget cuts.

Medsolve Dynamics — Tue, 17 Mar 2026 13:00:25 GMT

The conversation highlights the significant impact of budget cuts on oncology programs, particularly on capital decisions, pre-approved purchases, and service line expansion. It emphasizes the need for reevaluating assumptions and conducting a rigorous review of budget numbers in response to budget cuts.

Takeaways

Budget cuts impact capital decisions
Reevaluation of assumptions is crucial

Evaluate support gaps before signing up for AI or software solutions.

Medsolve Dynamics — Tue, 17 Mar 2026 12:58:53 GMT

The conversation explores the challenges of using AI tools developed by vendors and the importance of understanding support mechanisms. It emphasizes the need to evaluate support gaps before signing up for AI or software solutions.

Takeaways

Vendor support for AI tools
Understanding support mechanisms

Misconceptions and limitations of requesting a quote from a vendor.

Medsolve Dynamics — Tue, 17 Mar 2026 12:56:02 GMT

The conversation delves into the misconceptions and limitations of requesting a quote from a vendor, highlighting the importance of defining success before engaging in pricing discussions.

Takeaways

Vendor Perspective
Importance of Defining Success

The importance of ownership and preparation in the successful launch of new service lines.

Medsolve Dynamics — Tue, 17 Mar 2026 12:43:24 GMT

The challenges of operationalizing clinical plans and the impact of supply chain disruptions on service lines. The importance of ownership and preparation in the successful launch of new initiatives.

Takeaways

Operational challenges impact service lines
Preparation and ownership are crucial for successful launches

The importance of starting AI adoption with math, validating model accuracy.

Medsolve Dynamics — Tue, 17 Mar 2026 12:41:43 GMT

The conversation covers the importance of starting AI adoption with math, validating model accuracy, challenges with benchmarks, the review and sign-off process, and the impact of AI on business. It emphasizes the need to ask questions before signing AI paperwork to ensure it drives positive change.

Takeaways

AI adoption starts with math
Validate model accuracy on relevant data
Benchmarks may not reflect your practice
Consider who needs to review and sign off
AI should drive change, not just add cost
Ask questions before signing AI paperwork

The Importance of Understanding the Negotiation Structure

Medsolve Dynamics — Tue, 17 Mar 2026 12:40:44 GMT

Preparing for a capital meeting involves understanding the negotiation structure and being aware of vendor flexibility. Medsolve can assist in navigating this process effectively.

Takeaways

Negotiating within a structured framework
Vendor flexibility and pricing tiers

The role of Medsolve in providing a second set of eyes on projects.

Medsolve Dynamics — Tue, 17 Mar 2026 12:39:31 GMT

The conversation covers the importance of understanding and defining constraints, negotiating leverage, and the role of Medsolve in providing a second set of eyes on constraints.

Takeaways

Define your constraints
Leverage comes from understanding and defining your constraints

Preparation for a capital meeting & negotiating within a pre-mapped structure.

Medsolve Dynamics — Tue, 17 Mar 2026 12:38:24 GMT

The conversation covers the preparation for a capital meeting, understanding likely objections, rehearsed responses, negotiating within a pre-mapped structure, negotiating blind, and the value of Medsolve in negotiations.

Takeaways

Preparation is key to successful negotiations
Understanding the structure of negotiations is crucial for effective outcomes.

Negotiating with vendors requires a deep understanding of business assumptions and leverage points.

Medsolve Dynamics — Tue, 17 Mar 2026 12:37:16 GMT

Negotiating with vendors requires a deep understanding of business assumptions and leverage points. Preparation is key to successful negotiation.

Takeaways

Business assumptions are crucial
Preparation is key

Maximizing LINAC capacity for revenue generation.

Medsolve Dynamics — Tue, 17 Mar 2026 12:36:18 GMT

The conversation discusses the importance of maximizing LINAC capacity and optimizing referral flow, scheduling blocks, and protocol discipline for revenue generation in disease treatments like osteoarthritis and plantar fasciitis.

Takeaways

Efficient use of LINAC capacity is crucial for revenue generation
Referral flow, scheduling blocks, and protocol discipline are key for revenue generation

The challenges and considerations related to the implementation of AI tools in Oncology programs.

Medsolve Dynamics — Tue, 17 Mar 2026 12:34:51 GMT

The conversation explores the challenges and considerations related to the implementation of AI tools in programs. It delves into the evaluation framework, task automation, liability, KPIs for success, workflow changes, and the impact on schedule and review processes.

Takeaways

AI tools require a clear evaluation framework
Workflow changes are essential for AI implementation

The root causes of failed negotiations.

Medsolve Dynamics — Tue, 17 Mar 2026 12:33:40 GMT

The conversation delves into the complexities of oncology capital deals, highlighting the root causes of failed negotiations and the importance of alignment between deal structure and program needs. It also explores the impact of incorrect assumptions on costs and the significance of vendor relationships in this environment.

Takeaways

Capital negotiations root causes
Alignment between deal structure and program needs
Optimistic utilization projections
Vague service expectations
KPIs not tied to patient flow
Impact of incorrect assumptions on costs
Importance of vendor relationships

Structuring Capital and Service Agreements in Oncology Programs.

Medsolve Dynamics — Tue, 17 Mar 2026 12:31:56 GMT

Yoel Bakas has experience on the vendor side, helping oncology program structure capital and service agreements. He emphasizes the importance of validating and aligning assumptions before committing capital, as fixing issues after Go Live is expensive.

Takeaways

Capital and service agreements require multi-year operating commitments
Validating and aligning assumptions before committing capital is crucial

The Trap of Addressing Downstream Processes in AI implementations.

Medsolve Dynamics — Tue, 17 Mar 2026 12:29:04 GMT

The 2026 reimbursement change in radiation oncology has led to a focus on AI to protect margins and rebuild workflows. However, the trap lies in addressing downstream processes and avoiding bottlenecks.

Takeaways

2026 reimbursement change
AI to protect margins

Benign disease as a margin stabilizer.

Medsolve Dynamics — Tue, 17 Mar 2026 12:27:56 GMT

The conversation discusses the positioning of benign disease as a stabilizer and the impact of referral behavior on machine utilization.

Takeaways

Benign disease as a stabilizer
Referral behavior impacts machine utilization

Theranostics in radiation oncology requires deliberate design.

Medsolve Dynamics — Tue, 17 Mar 2026 12:25:24 GMT

Theranostics in radiation oncology requires a deliberate design of operational infrastructure to ensure ownership, growth, and clinical opportunity. The alignment of theranostics with radiation oncology impacts scheduling, flow, waste protocols, and coordination across departments.

Takeaways

Operational infrastructure is crucial for the success of theranostics in radiation oncology
Theranostics requires deliberate design and coordination across departments

The impact of thoughtful sequencing on technology success and failure.

Medsolve Dynamics — Tue, 17 Mar 2026 12:24:23 GMT

The impact of thoughtful sequencing on technology success and failure.

Takeaways

Sequencing is crucial for technology success
Operating model readiness is key for technology implementation

Capital decisions often fail due to unvalidated assumptions.

Medsolve Dynamics — Tue, 17 Mar 2026 12:22:35 GMT

Capital decisions often fail due to unvalidated assumptions and lack of reflection of reality. The fix is to validate reality before locking decisions.

Takeaways

Unvalidated assumptions lead to capital decision failures
Validate reality before locking decisions

Physicians need to translate clinical intent into financial implications.

Medsolve Dynamics — Tue, 17 Mar 2026 12:21:40 GMT

Physicians are increasingly involved in capital decisions, impacting clinic autonomy and program success. Clinical decisions now affect workflows, coverage models, and daily possibilities. Physicians need to translate clinical intent into operational and financial implications to ensure program sustainability.

Takeaways

Physicians' involvement in capital decisions impacts clinic autonomy and program success.
Physicians need to translate clinical intent into operational and financial implications for program sustainability.

Capital plans, AI investments, and margin pressure.

Medsolve Dynamics — Tue, 17 Mar 2026 12:18:52 GMT

Yoel Bakas discusses his focus on the conversations at ACRO and the challenges in healthcare administration, including capital plans, AI investments, and margin pressure.

Takeaways

ACRO conversations
Challenges in healthcare administration

Growth failure is often a result of execution issues.

Medsolve Dynamics — Tue, 17 Mar 2026 12:17:22 GMT

The conversation delves into the multifaceted nature of margin target challenges in oncology programs, highlighting the various factors that contribute to missed targets. It also emphasizes the importance of recognizing that growth failure is often a result of execution issues rather than the failure of the growth strategy.

Takeaways

Multiple factors contribute to missed margin targets in oncology programs.
Growth failure is often a result of execution issues, not the failure of the growth strategy.

Impact of the reimbursement change on capital plans.

Medsolve Dynamics — Tue, 17 Mar 2026 12:15:56 GMT

The conversation delves into the impact of the reimbursement change on capital plans and the hidden strategy gap in growth plans. It also explores the need for a sanity check in response to the changing landscape of healthcare delivery.

Takeaways

Reimbursement change impact
Hidden strategy gap

Medsolve Dynamics is just beginning.

Medsolve Dynamics — Tue, 17 Mar 2026 12:14:28 GMT

Yoel Bakas has spent 20 years in the medtech industry, focusing on structuring complex medtech deals and ensuring technology investments are mathematically successful. He shares a success story of unlocking $3 million in capital savings for a client and emphasizes the importance of preserving vendor relationships while ensuring hospital solvency. He expresses gratitude to his network and invites introductions for those navigating clinical ambition and financial pressure. The next chapter for Medsolve Dynamics is just beginning.

Takeaways

Medtech deal structuring
Closing the gap between ROI and P&L
Preserving vendor relationships